Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in CCND1, 2, 3 Amplified Tumors (MATCH Subprotocol Z1B)
NCT04439201Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- May 2016
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in malignant solid neoplasm, lymphoma, hematopoietic and lymphoid cell neoplasm, sponsored by National Cancer Institute. Started May 2016; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
malignant solid neoplasmlymphomahematopoietic and lymphoid cell neoplasm
Beyond the preview
Go deeper on NCT04439201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04439201.